PTC Therapeutics (PTCT) Expected to Announce Quarterly Earnings on Thursday

PTC Therapeutics (NASDAQ:PTCT) is projected to announce its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect PTC Therapeutics to announce earnings of $0.2317 per share and revenue of $298.1130 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.42. PTC Therapeutics had a negative net margin of 22.58% and a negative return on equity of 362.45%. The firm had revenue of $272.55 million during the quarter, compared to analysts’ expectations of $217.42 million. During the same quarter in the previous year, the company posted $10.04 EPS. PTC Therapeutics’s revenue was up 43.5% on a year-over-year basis. On average, analysts expect PTC Therapeutics to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

PTC Therapeutics Stock Performance

NASDAQ:PTCT opened at $78.40 on Thursday. The company has a market cap of $6.50 billion, a price-to-earnings ratio of -33.65, a P/E/G ratio of 4.72 and a beta of 0.53. PTC Therapeutics has a 52-week low of $43.17 and a 52-week high of $90.87. The stock’s fifty day moving average price is $76.97 and its two-hundred day moving average price is $72.81.

Analyst Ratings Changes

Several research firms recently issued reports on PTCT. Morgan Stanley reiterated an “overweight” rating and issued a $94.00 price target on shares of PTC Therapeutics in a report on Friday, May 8th. Cantor Fitzgerald upped their target price on shares of PTC Therapeutics from $124.00 to $130.00 and gave the company an “overweight” rating in a research report on Thursday, July 16th. Zacks Research raised shares of PTC Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 7th. Jefferies Financial Group raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating and raised their target price for the company from $76.00 to $85.00 in a research note on Wednesday, May 27th. Finally, Truist Financial upgraded shares of PTC Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $92.29.

Insider Buying and Selling at PTC Therapeutics

In other PTC Therapeutics news, Director Mary L. Smith sold 15,834 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $90.00, for a total value of $1,425,060.00. Following the completion of the sale, the director owned 21,813 shares of the company’s stock, valued at approximately $1,963,170. This represents a 42.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Neil Gregory Almstead sold 2,464 shares of the stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $90.25, for a total transaction of $222,376.00. Following the completion of the sale, the insider owned 60,299 shares in the company, valued at approximately $5,441,984.75. This trade represents a 3.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 198,662 shares of company stock valued at $16,347,994. Corporate insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PTCT. Public Employees Retirement System of Ohio bought a new stake in PTC Therapeutics during the 4th quarter worth approximately $126,000. Van ECK Associates Corp acquired a new position in shares of PTC Therapeutics in the fourth quarter valued at approximately $217,000. CIBC Private Wealth Group LLC acquired a new position in shares of PTC Therapeutics in the fourth quarter valued at approximately $191,000. Picton Mahoney Asset Management bought a new stake in shares of PTC Therapeutics during the fourth quarter worth $173,000. Finally, LPL Financial LLC acquired a new stake in shares of PTC Therapeutics during the fourth quarter worth $225,000.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.